HK Stock Market Move | METIS TECHBIO-P(07666) Rises Over 6% Again as Cross-Sector Giants Expand into AI4S Pharma, NanoForge Commercialization Results Enter a Period of Concentrated Release

METIS TECHBIO-P(07666) rose over 6% again, up 5.01% as of press time, at HK$17.62, with a turnover of HK$72.4299 million. On the news front, recently, according to market media reports, Anthropic has completed a wet lab in the San Francisco Bay Area of the United States, extending biological research from computer simulation to real experiments, and exploring the use of Claude to instruct Siasun Robot&Automation to conduct experiments. Soochow pointed out that global tech giants are deeply embedding into biomedicine through different paths, and AI pharma has entered a strategic entry phase. The dry-wet closed loop is the core operational logic chain of AIDD, and wet experiments are irreplaceable. BOC International believes that experimental validation is an important link for the AI pharma industry chain to realize long-term value, and the expansion of validation demand is expected to drive synchronous growth in demand for upstream research services such as gene synthesis and protein reagents. It is worth mentioning that in the first half of the year, the commercialization results of METIS TECHBIO's NanoForge entered a period of concentrated release, with revenue during the period exceeding RMB 154 million, surpassing last year's full-year revenue by 47%. Since the release of NanoForge, the world's first AI nano-delivery platform, METIS TECHBIO's pioneering new R&D paradigm of "dry experiments + wet experiments + intelligent agents" has fully covered the complete chain of AI protein generation, in vivo delivery technology, and next-generation immunotherapy development, forming a continuously learning R&D closed loop and nano-delivery data barriers, achieving continuous breakthroughs in extrahepatic delivery, and providing underlying support for the exploration of AI precision delivery and cell programming.